tbuckley/cabot-search huggingface dataset:
Perception of Atrial Fibrillation Before and After Radiofrequency Catheter Ablation
Authors: GerhardHindricks, ChristopherPiorkowski, HildegardTanner, RichardKobza, Jin-HongGerds-Li, CorradoCarbucicchio, HansKottkamp
Journal: Circulation (2005)

Background— The objective of this study was to assess the incidence and impact of asymptomatic arrhythmia in patients with highly symptomatic atrial fibrillation (AF) who qualified for radiofrequency (RF) catheter ablation. Methods and Results— In this prospective study, 114 patients with at least 3 documented AF episodes together with corresponding symptoms and an ineffective trial of at least 1 antiarrhythmic drug were selected for RF ablation. With the use of CARTO, circumferential lesions around the pulmonary veins and linear lesions at the roof of the left atrium and along the left atrial isthmus were placed. A continuous, 7-day, Holter session was recorded before ablation, right after ablation, and after 3, 6, and 12 months of follow-up. During each 7-day Holter monitoring, the patients recorded quality and duration of any complaints by using a detailed symptom log. More than 70 000 hours of ECG recording were analyzed. In the 7-day Holter records before ablation, 92 of 114 patients (81%) had docume...
Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients
Authors: G. Lombardi, P. Del Bianco, A.A. Brandes, M. Eoli, R. Rudà, T. Ibrahim, I.R. Lolli, A. Pace, B. Daniele, F. Pasqualetti, S. Rizzato, E. Bergo, M. Caccese, M. Padovan, R. Soffietti, G.L. De Salvo, V. Zagonel
Journal: Annals of Oncology (2019)
High quality health systems in the SDG era: Country-specific priorities for improving quality of care
Authors: Gagan Thapa, Manoj Jhalani, Sebastián García-Saisó, Address Malata, Sanam Roder-DeWan, Hannah H. Leslie
Journal: PLoS Medicine (2019)

Long a concern in high-income countries, health system quality emerged as a truly global priority in 2018.Three major reports [1-3] and an increasing body of empirical work (e.g., [4][5][6]) identified deep and pervasive deficits in quality undermining progress toward the Sustainable Development Goal (SDG) of health and wellness for all by 2030.Whether this attention translates into effective action in the near future will depend on national leaders seizing the opportunity to change health systems for improved outcomes.How can policymakers and researchers coordinate to ensure that action is informed by evidence and that policy changes are assessed for generalizable insight?To address this question, we gathered leaders in global health active along a spectrum from generating insight in individual studies to making policy that affects millions of individuals and present some of their thoughts here.All have identified health system quality as a key element of progress; each brings a distinct perspective on what change will require in their country or context.As those setting the agenda in countries from India to Mexico, how do they see the future for health system quality?What is needed from the research community to accelerate progress towards improved health?From Nepal, Gagan Thapa argues that strong political commitment is required to ensure that each individual has access to affordable and quality healthcare.Political actors need to be informed about issues related to affordability and other quality issues related to health services and have the political will to resolve them.Critical reform areas such as medical education, procurement of medicines, minimum quality standards, regulation, and partnerships with the private sector will require meaningful engagement of lawmakers as well as their commitment to increases in national budgets for health.People in all countries must be empowered to demand health services that are responsive to their health needs.We have to be better at giving people platforms to express their health needs by including citizen voices during policymaking, budgeting, and planning processes of governments.Yet people are ill-informed about their rights to access quality and affordable healthcare.All too often, people do not access care because it is too expensive, inconvenient, remote from their household, or insensitive to their cultural practices.Many face catastrophic expenditures because of the high costs of surgery, medicines, and related costs for travel and accommodation.We need to have the political courage to include citizen voices in government
Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN
Authors: K.N. Chi, S. Thomas, N. Agarwal, F. Feng, G. Attard, A.W. Wyatt, M. Gormley, D.S. Ricci, A. Lopez-Gitlitz, K. Deprince, J. Larsen, W. Chen, B. Miladinovic, V. Naini, S. Chowdhury
Journal: Annals of Oncology (2019)
Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot
Authors: Mathieu Mateo, Stéphanie Reynard, Xavier Carnec, Alexandra Journeaux, Nicolas Baillet, Justine Schaeffer, Caroline Picard, Catherine Legras-Lachuer, Richard Allan, Emeline Perthame, Kenzo-Hugo Hillion, Natalia Pietrosemoli, Marie-Agnès Dillies, Laura Barrot, Audrey Vallve, Stéphane Barron, Lyne Fellmann, Jean-Charles Gaillard, Jean Armengaud, Caroline Carbonnelle, Hervé Raoul, Frédéric Tangy, Sylvain Baize
Journal: Science Translational Medicine (2019)

Lassa fever is a major threat in Western Africa. The large number of people living at risk for this disease calls for the development of a vaccine against Lassa virus (LASV). We generated live-attenuated LASV vaccines based on measles virus and Mopeia virus platforms and expressing different LASV antigens, with the aim to develop a vaccine able to protect after a single shot. We compared the efficacy of these vaccines against LASV in cynomolgus monkeys. The vaccines were well tolerated and protected the animals from LASV infection and disease after a single immunization but with varying efficacy. Analysis of the immune responses showed that complete protection was associated with robust secondary T cell and antibody responses against LASV. Transcriptomic and proteomic analyses showed an early activation of innate immunity and T cell priming after immunization with the most effective vaccines, with changes detectable as early as 2 days after immunization. The most efficacious vaccine candidate, a measles vector simultaneously expressing LASV glycoprotein and nucleoprotein, has been selected for further clinical evaluation.
Associations of PGK1 promoter hypomethylation and PGK1‐mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan‐cancer analysis
Authors: Fei Shao, Xueying Yang, Wei Wang, Juhong Wang, Wei Guo, Xiaoli Feng, Susheng Shi, Qi Xue, Shugeng Gao, Yibo Gao, Zhimin Lu, Jie He
Journal: Cancer Communications (2019)

Abstract Background Cancer cells reprogram metabolism for proliferation. Phosphoglycerate kinase 1 (PGK1), as a glycolytic enzyme and newly identified protein kinase, coordinates glycolysis and mitochondrial metabolism. However, the clinical significance of PGK1 expression and function in cancer progression is unclear. Here, we investigated the relationship between the progression and prognosis of multiple cancer types and PGK1 expression and its function in the mitochondrial metabolism regulation. Methods We performed pan‐cancer analyses of PGK1 mRNA level and DNA methylation in 11,908 tumor tissues and 1582 paired normal tissues across 34 cancer types in The Cancer Genome Atlas datasets. Using specific antibodies against PGK1 S203 and PDHK1 T338 phosphorylation, we performed immunohistochemistry with tissue microarray assay in additional 818 cancer cases with 619 paired normal tissues from five cancer types. Results The PGK1 mRNA level was significantly elevated with hypomethylation in promotor regions and associated with advanced TNM stage in 15 and four cancer types, respectively. In breast carcinoma, elevated PGK1 mRNA level and promoter hypomethylation were associated with poor prognosis. Positively correlated PGK1 S203 and PDHK1 T338 phosphorylation levels were significantly associated with short overall survival (OS) in cancers of the breast, liver, lung, stomach, and esophagus and with advanced TNM stage in breast and esophageal cancers. PGK1 pS203 and PDHK1 pT338 were also independent predictors of short OS in liver, lung, and stomach cancer. Conclusions The elevated expression, promoter hypomethylation, and phosphorylation of PGK1 and PDHK1 were related with disease progression and short OS in diverse types of cancer. PGK1 and PDHK1 phosphorylation may be potential prognostic biomarkers.
Risk factors for bacteremia-associated mortality of Aeromonas sobria in hematologic malignancies
Authors: G. De la Cruz-Kú, B.S. Valcarcel, M. Luján, A. Saavedra, R. Luque, E. Eyzaguirre, M.B. Sultanov, Z. Morante, S. Quintana, S.P. Neciosup Delgado, A. Holguín Ruíz, W. Vicente, D. Enriquez
Journal: Annals of Oncology (2019)
ACCURACY a phase (P) II trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): Preliminary safety and efficacy data
Authors: R. Ferrarotto, A. Ho, L.J. Wirth, J. Muzaffar, C. Rodriguez, E. Dekel, R.M. Walker, C. Nadri-Shay, A. Vergara-Silva
Journal: Annals of Oncology (2019)
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Authors: Ronald de Wit, Johann de Bono, Cora N. Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Gero Kramer, Jean-Christophe Eymard, Aristotelis Bamias, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Ásgerður Sverrisdóttir, Christine Theodore, Susan Feyerabend, Carole Helissey, Ayse Ozatilgan, Christine Geffriaud-Ricouard, Daniel Castellano
Journal: New England Journal of Medicine (2019)

The efficacy and safety of cabazitaxel, as compared with an androgen-signaling–targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear.
The prognostic significance of preoperative nutritional status in resected pancreatic ductal adenocarcinoma (PDAC)
Authors: S. Paiella, I. Trestini, I. Sperduti, M. Sandini, G. Elio, D. Melisi, A. Auriemma, C. Soldà, D. Tregnago, A. Avancini, E. Secchettin, D. Bonamini, G. Malleo, L. Gianotti, S. Pilotto, C. Bassi, M. Milella
Journal: Annals of Oncology (2019)
Radiomics of gastrointestinal stromal tumours, risk classification based on computed tomography images: A pilot study
Authors: M.J. Timbergen, M.P.A. Starmans, M. Vos, M. Renckens, D.J. Grünhagen, G J L H van Leenders, W.J. Niessen, C. Verhoef, S. Sleijfer, S. Klein, J.J. Visser
Journal: Annals of Oncology (2019)
H<sub>2</sub>O<sub>2</sub>‐Sensitive Upconversion Nanocluster Bomb for Tri‐Mode Imaging‐Guided Photodynamic Therapy in Deep Tumor Tissue
Authors: Wei Jiang, Chao Zhang, Arsalan Ahmed, Yunlei Zhao, Yu Deng, Yin Ding, Jianfeng Cai, Yong Hu
Journal: Advanced Healthcare Materials (2019)

Abstract Low penetration depth of excited light, undesirable distribution of photosensitizers, severe hypoxia, and inefficient reactive oxygen species (ROS) generation in tumors, lead to the poor therapeutic effects in photodynamic therapy. Herein, a multifunctional nanocluster bomb (UCGM naonoparticles) composed of upconversion nanoparticles (NPs), CeO x , graphite‐C 3 N 4 (g‐C 3 N 4 ) NPs, and metformin (Met) are developed to mitigate the hypoxia by oxidizing H 2 O 2 into O 2 due to the catalysis of CeO x . The presence of Met can act on the mitochondrion to inhibit the respiration of tumor cells, further improving the O 2 level. Meanwhile, g‐C 3 N 4 NPs are released from UCGM NPs and penetrate tumor tissue deeply because of their small size. Upon 808 nm laser illumination, UCGM NPs show remarkable photothermal ability and efficiently convert near infrared to ultraviolet light to activate the g‐C 3 N 4 NPs to generate ROS in a whole tumor to facilitate a combined antitumor effect against deeply located tumors. Moreover, these UCGM NPs also display excellent performances in upconversion luminescence, magnetic resonance imaging, and computerized tomographic imaging, making them a potential imaging‐guided drug delivery system in cancer therapy.
Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study
Authors: F. Barlesi, D.-W. Kim, E.M. Bertino, M.J. van den Bent, H. Wakelee, P.Y. Wen, P. Garrido Lopez, S. Orlov, M. Majem, M. McKeage, C.-J. Yu, F.K. Hurtado, P. Cazorla Arratia, Y. Song, F. Branle, M. Shi, L.Q. Chow
Journal: Annals of Oncology (2019)
Population Level Survival for Patients with Rare Hematologic Malignancies in the United States in the Early 21st Century
Authors: Dianne Pulte, Janick Weberpals, Lina Jansen, Alexander Katalinic, Alice Nennecke, Bernd Holleczek, Meike Ressing, Sabine Luttmann, Hermann Brenner
Journal: Blood (2016)
Immunodeficient Mice Are Poor Mobilizers -Novel Evidence That Demonstrates a Pivotal Role of Complement in Triggering Mobilization of HSPC.
Authors: Ryan Reca, Marcin Wysoczynski, Richard Hansen, Magda Kucia, Anna Janowska-Wieczorek, Janina Ratajczak, Mariusz Z. Ratajczak
Journal: Blood (2005)
Anti-HER-2 therapies and left ventricular dysfunction the renaissance study
Authors: A.J. Daniele, V. Gregorietti, A. Aguilar, C. Almada, V. Lopez, M. Savignano, G. Roganovich, N. Kassis, A D´ Ortencio, S. Daniele, M.V. Cáceres
Journal: Annals of Oncology (2019)
Radiographic characteristics and poor prognostic factors of interstitial lung disease (ILD) in nivolumab-treated patients with non-small cell lung cancer (NSCLC)
Authors: S. Sasaki, K. Oikado, Y. Saito, J. Tominaga, M. Sata, F. Sakai, T. Kato, T. Iwasawa, H. Kenmotsu, M. Kusumoto, T. Baba, M. Endo, Y. Fujiwara, H. Sugiura, N. Yanagawa, Y. Ito, T. Sakamoto, Y. Ohe, K. Kuwano
Journal: Annals of Oncology (2019)
AIEgens Barcodes Combined with AIEgens Nanobeads for High-sensitivity Multiplexed Detection
Authors: Weijie Wu, Xun Wang, Mengfei Shen, Li Li, Yue Yin, Lisong Shen, Weiwei Wang, Daxiang Cui, Jian Ni, Xiaoyuan Chen, Wanwan Li
Journal: Theranostics (2019)

Suspension arrays based on optical encoded microspheres have attracted great attention for multiplexed detection in gene analysis, protein profiling, early disease diagnosis, treatment monitoring and so on. However, the fluorescence stability of barcodes and detection sensitivity require further improvement to meet the increasing demands of "precision diagnosis". Methods: This work reports a novel suspension array platform based on extremely stable AIEgens (AIE33 and AIE NIR800) microbeads as barcodes and AIEgens (1,1,2,3,4,5-Hexaphenyl-1H-silole, HPS) nanobeads as fluorescent signal reporter coupled with flow cytometry for multiplexed detection. Results: Due to the excellent fluorescent signal amplification effect of the HPS nanobeads, our multiplex assay showed enhanced detection sensitivity, compared to multiplex assay using QDs nanobeads (up to 3-fold improvement) and commercial organic dye of phycoerythrin (up to 5-fold improvement) as the fluorescent signal reporters. Conclusion: Furthermore, validating experiments showed similar detection performance to the clinical gold-standard method of ImmunoCAP for allergen detection in patient serum samples, demonstrating the suspension array platform based on AIEgens microbeads with excellent fluorescence stability and AIEgens nanobeads with strong signal amplification ability is promising for high-sensitivity multiplexed bioassay applications.
Open label phase III study of arfolitixorin vs leucovorin in mFOLFOX-6 for first-line treatment of metastatic colorectal cancer: AGENT
Authors: J. Tabernero, G. Prager, S. Stintzing, H.J. Lenz, H.P. Nygren, C. Papadimitriou
Journal: Annals of Oncology (2019)
Prevention of chemoradiation-related mucositis in patients with head and neck cancer using dexamethasone-based mouthwash: A phase II randomized double-blind, placebo-controlled study
Authors: N. Prasongsook, P. Kaewvatee, C. Ajalanond, S. Srichamchan, K. Seetalarom
Journal: Annals of Oncology (2019)
Is immuno-oncology therapy effective in hypermutator glioblastomas with somatic or germline mutations?
Authors: C. Kamiya-Matsuoka, N. Metrus, S.-P. Weathers, J. Ross, K. Shaw, M. Penas-Prado, M. Loghin, K. Alfaro-Munoz, B. O’Brien, R. Harrison, Z. Sadighi, N. Majd, W. Yung, F. Meric-Bernstam, D. Hambardzumyan, J. de Groot
Journal: Annals of Oncology (2019)
Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal cancer (PLATO-ACT5)
Authors: A. Gilbert, L. McParland, J. Webster, S. Bell, J. Copeland, R.A. Adams, M. Harrison, R. Muirhead, A. Renehan, D. Sebag-Montefiore, M.A. Hawkins
Journal: Annals of Oncology (2019)
Response rates and lesion-level progression patterns of solid tumor patients in an academic phase I program: implications for tumour heterogeneity
Authors: C. Chen, C. Pinto, C. Walmsley, R. Allen, A. Muzikansky, L. Henderson, M. Broudo, J. Wolfgang, D.M. Fitzgerald, T. Hong, D. Juric
Journal: Annals of Oncology (2019)
Phase I trial of CV301 in combination with anti-PD-1 therapy in non-squamous NSCLC
Authors: A. Rajan, J.E. Gray, S. Devarakonda, J. Gurtler, R. Birhiray, E. Paschold, A. Dasgupta, C. Heery, C. Pico-Navarro, M. Piechatzek, E. Wagner, E. Menius, R.N. Donahue, J. Schlom, J.L. Gulley
Journal: Annals of Oncology (2019)
Abstract 15853: Identification of Several Novel Loci for Coagulation and Fibrinolysis
Authors: Shaoteng Wang, Chan E Hong, James Perry, Keith Tanner, Braxton D Mitchell, Alan R Shuldiner, Mao Fu
Journal: Circulation (2017)

Introduction: Thrombosis and fibrinolysis is implicated in the progression and incidence of clinically apparent atherosclerotic cardiovascular diseases (CVDs), such as myocardial infarction and str...
Pyogenic Brain Abscesses in a Patient With Digital Clubbing
Authors: Vimal Kumar Paliwal, Sucharita Anand, Vivek Singh
Journal: JAMA Neurology (2019)

A man presents with headache, double vision, and seizures for 1 month. Cranial magnetic resonance imaging showed 2 ring-enhancing brain lesions with thin-walled, contrast-enhancing rims and central liquefaction. What is your diagnosis?
Soluble programmed death-ligand 1 indicate poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization
Authors: X. Ma, X. Qu, W. Yang, H. Wang, B. Wang, M. Shen, Y. Zhou, C.Y. Zhang, Y. Sun, J. Chen, B. Hu, Z. Gong, X. Zhang, B. Pan, J. Zhou, J. Fan, X. Yang, W. Guo
Journal: Annals of Oncology (2019)
Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial
Authors: J. Masliah-Planchon, M. Kamal, E. Borcoman, E. Girard, P. Gestraud, G. Bataillon, A. Vincent-Salomon, C. Lecerf, C. Callens, S. Antonio, C. Franck, O. Mariani, I. Bieche, C. Le Tourneau, V. Servois
Journal: Annals of Oncology (2019)
Tumour microvessel density for predicting nintedanib activity: Data from the randomized CHIVA trial (a GINECO study)
Authors: M. Villemin, N. Elie, C. Blanc-Fournier, G. De Rauglaudre, N. Raban, A. Chevalier, G. Ferron, M.-C. Kaminsky-Forrett, F. Beurrier, S. Hamizi, P. Combe, S Abadie Lacourtoisie, J. Meunier, A. Floquet, J. Alexandre, L. Venat-Bouvet, C. Louvet, L. Favier, I. Licaj, J. Florence
Journal: Annals of Oncology (2019)
Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate
Authors: Oukseub Lee, Megan E. Sullivan, Yanfei Xu, Chiara Rogers, Miguel Muzzio, Irene Helenowski, Ali Shidfar, Zexian Zeng, Hari Singhal, Borko Jovanovic, Nora Hansen, Kevin P. Bethke, Peter H. Gann, William Gradishar, J. Julie Kim, Susan E. Clare, Seema A. Khan
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Selective progesterone receptor modulators (SPRMs) show preclinical activity against hormone-sensitive breast cancer, but have not been tested in patients with early, treatment-naïve tumors. Patients and Methods: In a double-blind presurgical window trial of oral telapristone acetate (TPA) 12 mg daily versus placebo, 70 patients with early-stage breast cancer were randomized 1:1 (stratified by menopause) and treated for 2 to 10 weeks. The primary endpoint was change in Ki67 between diagnostic biopsy and surgical specimens. Gene expression pre- and posttherapy was assessed using RNA-sequencing and gene set enrichment analysis was performed to determine pathways enriched in response to TPA and placebo treatments. Results: Among 61 evaluable women (29 placebo and 32 telapristone acetate), 91% of tumors were ER/PR positive. The mean Ki67 declined by 5.5% in all women treated with telapristone acetate (P = 0.003), and by 4.2% in all women treated with placebo (P = 0.04). After menopausal stratification, the Ki67 decline remained significant in 22 telapristone acetate–treated premenopausal women (P = 0.03). Differential gene expression analysis showed no significant modulation overall. However, in a subset of tumors that demonstrated ≥30% relative reduction in Ki67 in the telapristone acetate group, genes related to cell-cycle progression, and those in the HER2 amplicon were significantly downregulated. In contrast, no significantly enriched pathways were identified in the placebo group. Conclusions: Patients treated with telapristone acetate whose Ki67 decreased by ≥30% demonstrated a selective antiproliferative signal, with a potentially important effect on HER2 amplicon genes. Evaluation of SPRMs in a neoadjuvant trial is merited, with attention to predictors of response to SPRM therapy, and inclusion of pre- and postmenopausal women.
A Novel Application of [18F]Fluorothymidine-PET ([18F]FLT-PET) in Clinical Practice to Quantify Regional Bone Marrow Function in a Patient With Treatment-Induced Cytopenias and to Guide “Marrow-Sparing” Radiotherapy
Authors: Belinda A. Campbell, Michael S. Hofman, H. Miles Prince
Journal: Clinical Nuclear Medicine (2019)

Abstract 18 F-Fluorothymidine-positron emission tomography with CT fusion ([ 18 F]FLT-PET/CT) offers a unique and non-invasive method for three-dimensional localization and quantification of functional bone marrow. [ 18 F]FLT-PET/CT has potential application in radiotherapy planning when risk of marrow toxicity is a significant clinical concern. In this patient with chemo-refractory, transformed lymphoma and treatment-induced cytopenias, [ 18 F]FLT-PET/CT was a novel and useful adjunct to (1) image the distribution of functional bone marrow reserve, (2) guide “marrow-sparing” radiotherapy planning, and (3) quantify the effects of radiotherapy-induced bone marrow suppression both in-field and out-of-field.
Synergistic activity between niraparib and chemotherapy in colorectal cancer: Molecular determinants from a preclinical model
Authors: P.P. Vitiello, D. Ciardiello, C. Cardone, G. Martini, V. Belli, C. Borrelli, L. Poliero, G. Arrichiello, V. De Falco, E.F. Giunta, M. Terminiello, T. Troiani, F. Ciardiello, E. Martinelli
Journal: Annals of Oncology (2019)